Latest News

Andreessen Horowitz, Eli Lilly to release $500 million venture fund

Venture capital company Andreessen Horowitz said on Friday it was working with Eli Lilly to launch a $500 million venture fund that will be completely moneyed by the U.S. drugmaker.

WHY IT is very important The fund, Biotech Ecosystem Venture Fund, intends to buy potentially appropriate treatment platforms and innovative. innovation companies with special focus on new science,. engineering technologies and expert system. capabilities.

Beyond the capital contribution, Lilly would provide. extra resources to the companies, including an access to. its pre-clinical and clinical drug development talent and. resources. CONTEXT. Investing in drug advancement has actually slowed considering that early 2023 due to. higher rates of interest, however with alleviating inflationary pressures,. increasing bets of a soft landing for the U.S. economy and. appealing information from drug trials, the biotech financing market. began to see an increase last year.

These companies, which are greatly depending on credit are amongst. those that stand to benefit the most from the U.S. reserve bank. decreasing its loaning costs.

CRUCIAL QUOTE. Combining our strengths as organizations will empower founders. with not only the venture support needed to advance. groundbreaking innovations, but likewise the resources required to. strategically select the most promising application locations for. these platforms, stated Vineeta Agarwala, general partner at. Andreessen Horowitz's Bio + Health Fund.

(source: Reuters)